Worst Performing Stocks for Tax Loss Selling – Wolfe
Stifel Downgrades Biogen on Slow Alzheimer's Drug Launch, Uncertainty Ahead
Netflix, Ford, Biogen: Trending Tickers
Stifel Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $175
Stifel Downgrades Biogen to Hold From Buy, Adjusts Price Target to $175 From $275
Palantir, MicroStrategy Could Be Added to Nasdaq 100 Friday. Moderna, Super Micro Could Be Dropped.
Biogen Stock Touches 52-week Low at $153.55 Amid Challenges
Biogen ALS Drug Needs to Be Covered by MA Plans, CMS Says
Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials?
N-Lorem Foundation's Nano-rare Patient Colloquium Draws More Than 750 Attendees, Reinforcing Need for Treatment Options for People With Nano-rare Illnesses
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can XAI, Nvidia Help Stabilize Trajectory?
MicroStrategy Stock Could Get Added to the Nasdaq 100 Because of a Quirk
Biogen Reinstated With a Neutral at BofA
BofA Restarts Coverage of 11 Large-cap Biopharmas
B of A Securities Reinstates Neutral on Biogen, Announces $178 Price Target
Biogen Cut at Jefferies as '2025 Has a Tough Setup'
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Biogen Analyst Ratings
Jefferies Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $180
Biogen's Modest Growth Prospects and Revenue Challenges Highlighted in Hold Rating